Although the company reported strong second-quarter results and raised its guidance, shares of Hims & Hers Health (NYSE: HIMS) slipped immediately after its earnings announcement. Nonetheless, the stock has been a strong performer this year, up over 80%.

Let's take a look at the telehealth company's most recent results, and decide whether it still makes sense to buy the stock on this recent pullback.

Hims & Hers continues to see strong growth, with revenue surging 53% to $315.6 million. That was well above the company's guidance for $292 million to $297 million. Its net orders climbed 20% to 2.53 million, while average order value (AOV) climbed 27% to $121.

Continue reading

Source Fool.com